13.65
-0.23(-1.66%)
Currency In USD
| Previous Close | 13.88 |
| Open | 13.78 |
| Day High | 14.28 |
| Day Low | 13.44 |
| 52-Week High | 14.32 |
| 52-Week Low | 5.68 |
| Volume | 920,945 |
| Average Volume | 1.01M |
| Market Cap | 806.39M |
| PE | -4.11 |
| EPS | -3.32 |
| Moving Average 50 Days | 11.22 |
| Moving Average 200 Days | 8.67 |
| Change | -0.23 |
If you invested $1000 in Cullinan Therapeutics, Inc. (CGEM) since IPO date, it would be worth $456.37 as of February 21, 2026 at a share price of $13.65. Whereas If you bought $1000 worth of Cullinan Therapeutics, Inc. (CGEM) shares 3 years ago, it would be worth $1,242.04 as of February 21, 2026 at a share price of $13.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational